Clinical Trial

A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Study acronym: InsigHHT
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to: * evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers * evaluate the efficacy, safety, tolerability and PD of multiple doses of ALN-6400 in adult patients with HHT
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-15
notable Enrollment reduced: 120 -> 89 participants 2026-07-15
notable Trial sites expanded: 8 -> 16 locations 2026-05-02
Trial Details
NCT Number NCT06659640
Lead Sponsor Alnylam Pharmaceuticals
Conditions Hereditary Hemorrhagic Telangiectasia
Enrollment 89 participants
Start Date 2024-11-07
Primary Completion 2028-01-05 (estimated)
Study Completion 2028-06-22 (estimated)
Updated on ClinicalTrials.gov 2026-08-12